GlaxoSmithKline Pharmaceuticals · NSE: GLAXO · BSE: 500660
Q4 FY20 results · Jan–Mar 2020
GlaxoSmithKline Pharmaceuticals reported revenue from operations of ₹775.80 crore and net profit of ₹138.07 crore for Q4 FY20 (Jan–Mar 2020), on a consolidated basis.
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 775.80 | 0.00 | — | 778.59 | −0.4% |
| Other income | 15.82 | 0.00 | — | 16.50 | −4.1% |
| Total income | 791.62 | 0.00 | — | 795.09 | −0.4% |
| Profit before tax | 176.55 | 0.00 | — | (634.32) | Turned profit |
| Net profit for the period | 138.07 | 0.00 | — | (661.16) | Turned profit |
| EPS, basic (₹) | 8.15 | 0.00 | — | (39.03) | Turned profit |
| Net margin (%) | 17.8 | — | -84.9 |
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 775.88 | 751.22 | +3.3% | 778.68 | −0.4% |
| Other income | 15.16 | 52.46 | −71.1% | 16.25 | −6.7% |
| Total income | 791.04 | 803.68 | −1.6% | 794.93 | −0.5% |
| Profit before tax | 176.41 | 199.16 | −11.4% | (617.31) | Turned profit |
| Net profit for the period | 137.94 | 123.03 | +12.1% | (644.14) | Turned profit |
| EPS, basic (₹) | 8.14 | 7.26 | +12.1% | (38.02) | Turned profit |
| Net margin (%) | 17.8 | 16.4 | -82.7 |
Consolidated
- Filed with BSE
- 19 May 2020, 08:51 IST
- Board meeting
- 18 May 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 19 May 2020, 08:51 IST
- Board meeting
- 18 May 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE